Walk with a Future Doc program allows Canadian medical students to promote physical activity and health education in local communities.

Medical student-led walk and talk programs, such as Walk with a Future Doc (WWAFD), provide a means for the medical community and community at-large to interact in a non-clinical setting. This environment can increase attendance accountability, enhance patient-provider relationships, and allow medical professionals to be leading examples of healthy, active living. We demonstrate the positive interest for this program, rationale of participants for joining, and the feasibility of its setup. As one of the only WWAFD programs in Canada, we encourage other medical schools to implement this program to promote continuity of hands-on, community-engaged learning amongst their students.

Les programmes de marche et de discussion menés par les étudiants en médecine, tels que Walk with a Future Doc (WWAFD), permettent à la communauté médicale et à la communauté dans son ensemble d'interagir dans un cadre non clinique. Cet environnement peut accroître la responsabilité face à l'assiduité, améliorer les relations patient-fournisseur et permettre aux professionnels de la santé d'être des exemples de vie saine et active. Nous démontrons l'intérêt positif de ce programme, les raisons pour lesquelles les participants y adhèrent et la faisabilité de sa mise en place. Comme il s'agit de l'un des seuls programmes WWAFD au Canada, nous encourageons les autres facultés de médecine à mettre en œuvre ce programme pour promouvoir la continuité de l'apprentissage pratique et engagé au sein de la communauté parmi leurs étudiants.

ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma.

Glioblastoma is the most common primary brain tumor in adults. While the introduction of temozolomide chemotherapy has increased long-term survivorship, treatment failure and rapid tumor recurrence remains universal. The transcriptional regulatory protein, inhibitor of DNA-binding-1 (ID1), is a key regulator of cell phenotype in cancer. We show that CRISPR-mediated knockout of ID1 in glioblastoma cells, breast adenocarcinoma cells, and melanoma cells dramatically reduced tumor progression in all three cancer systems through transcriptional downregulation of EGF, which resulted in decreased EGFR phosphorylation. Moreover, ID1-positive cells were enriched by chemotherapy and drove tumor recurrence in glioblastoma. Addition of the neuroleptic drug pimozide to inhibit ID1 expression enhanced the cytotoxic effects of temozolomide therapy on glioma cells and significantly prolonged time to tumor recurrence. Conclusively, these data suggest ID1 could be a promising therapeutic target in patients with glioblastoma. SIGNIFICANCE: These findings show that the transcriptional regulator ID1 is critical for glioblastoma initiation and chemoresistance and that inhibition of ID1 enhances the effect of temozolomide, delays tumor recurrence, and prolongs survival.